ARDS - Aridis surges 36% after COVID cocktail neutralizes delta variant in preclinical model

ClaudioVentrella/iStock via Getty Images Aridis Pharmaceuticals ("ARDS") says an animal model demonstrated that its COVID-19 monoclonal antibody ("mAb") cocktail, AR-712, was effective at neutralizing the delta variant. AR-712, designed for inhaled delivery, is a combination of two fully human immunoglobulin G1 mAbs discovered from screening the antibody secreting B-cells of convalescent SARS-CoV-2 virus infected patients. The company plans to finalize a phase 1/2/3 program design and start the study in the second half of the year. Aridis shares are up 36% to $9.94 in after-hours trading.

For further details see:

Aridis surges 36% after COVID cocktail neutralizes delta variant in preclinical model